Analysts See $-0.01 EPS for Neovasc Inc. (NVCN)

March 11, 2018 - By Ellis Scott

 Analysts See $ 0.01 EPS for Neovasc Inc. (NVCN)

Analysts expect Neovasc Inc. (NASDAQ:NVCN) to report $-0.01 EPS on March, 22.They anticipate $0.48 EPS change or 102.13 % from last quarter’s $0.47 EPS. After having $-0.06 EPS previously, Neovasc Inc.’s analysts see -83.33 % EPS growth. The stock decreased 4.65% or $0.0094 during the last trading session, reaching $0.1927. About 37.51 million shares traded or 577.38% up from the average. Neovasc Inc. (NASDAQ:NVCN) has declined 19.02% since March 11, 2017 and is downtrending. It has underperformed by 35.72% the S&P500.

Neovasc Inc. (NASDAQ:NVCN) Ratings Coverage

Among 3 analysts covering Neovasc (NASDAQ:NVCN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Neovasc had 7 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, August 26 by Zacks. As per Wednesday, October 7, the company rating was initiated by JMP Securities. Canaccord Genuity maintained it with “Buy” rating and $15 target in Tuesday, August 25 report. The rating was initiated by Ladenburg Thalmann on Thursday, December 10 with “Buy”. The rating was downgraded by Zacks on Wednesday, August 12 to “Buy”. The stock of Neovasc Inc. (NASDAQ:NVCN) has “Neutral” rating given on Friday, May 20 by Ladenburg Thalmann.

Neovasc Inc., a specialty medical device company, develops, makes, and markets cardiovascular devices worldwide. The company has market cap of $24.98 million. The Company’s products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. It has a 0.76 P/E ratio. The firm also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: